On today’s episode of Free Lunch, Ryan McQueeney chats with Zacks Stock Strategist Dave Borun about the top cannabis investing storylines to watch in 2019, including new legal issues, the most exciting areas for growth, and a new model portfolio that will feature some of the industry’s top stocks.
Want more video content from Zacks? Subscribe to Zacks Investment News now!
Free Lunch is presented by Zacks Investment Research. It is streamed live, four times per week, and features breaking news and analysis from Zacks strategists. Free Lunch is available on YouTube, Twitter, and other major streaming platforms.
The cannabis industry exploded onto the mainstream in 2018, as legalization in Canada sparked several notable pure-play listings on U.S. exchanges and new regulations opened the door for broader American hemp and CBD industries.
Investing in cannabis stocks is captivating to wide audiences because it offers almost unparalleled growth potential. New markets could open up around the world, many products and applications are yet to be invented, and massive business deals are still on the horizon.
That said, plenty of movement is already being made. Beer maker Constellation Brands (STZ - Free Report) has purchased a sizeable stake of Canopy Growth (CGC - Free Report) . Tobacco giant Altria (MO - Free Report) scooped up exposure to Cronos Group (CRON - Free Report) . Even Coca-Cola (KO - Free Report) mentioned that it is exploring possibilities in the world of CBD-based drinks.
There’s also been significant changes to the regulatory environment recently. For instance, the 2018 Farm Bill legalized the production of hemp in the United States, paving the way for a more structured CBD industry.
On today’s episode of Free Lunch, Ryan and Dave discuss all of these storylines. The pair also speculate about the near-term future of the business, including potential M&A deals. Further, Dave explains how investors can take lessons learned in the biotech, retail, and agriculture industries and apply them to different segments of the cannabis market.
Finally, Dave provides a brief preview of Zacks’ upcoming cannabis-focused portfolio service, which will feature both buy and sell recommendations and breaking industry news and commentary. Want to know what to expect from this service? Interested in the future of cannabis investing? Don’t miss today’s episode of Free Lunch!
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
See them today for free >>